title: Incorporating equity-efficiency interactions in cost-effectiveness analysis-three approaches applied to breast cancer control.
abstract: BACKGROUND
  The past decade, medical technology assessment focused on cost-effectiveness analysis, yet there is an increasing need to consider equity implications of health interventions as well. This article addresses three equity-efficiency trade-off methods proposed in the literature. Moreover, it demonstrates their impact on cost-effectiveness analyses in current breast cancer control options for women of different age groups.
  
  
  METHODS
  We adapted an existing breast cancer model to estimate cost-effectiveness and equity effects of breast cancer interventions. We applied three methods to quantify the equity-efficiency trade-offs: 1) targeting specific groups, comparing disparities at baseline and in different intervention scenarios; 2) equity weighting, valuing low and high health gains differently; and 3) multicriteria decision analysis, weighing multiple equity and efficiency criteria. We compared the resulting composite league tables of all approaches.
  
  
  RESULTS
  The approaches show that a comprehensive breast cancer program, including screening, for women below 75 years of age was most attractive in both the group targeting approach and the equity weighting approach. Such control programs would reduce disparities with 56% and at euro1908 per equity quality-adjusted life-year gained. In the multicriteria approach, a comprehensive treatment program for women below 75 years of age and treatment in stage III breast cancer were most attractive, with both an 82% selection probability, followed by screening programs for the two age groups.
  
  
  CONCLUSIONS
  In the three equity weighing approaches, targeting women below 75 years of age was more cost-effective and led to more equitable distributions of health. This likely is similar in other fatal diseases with similar age distributions. The approaches may lead to different outcomes in nonfatal disease.
authors.affiliation: Institutes of Health Policy & Management and of Medical Technology Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands.
authors.forename: Stefan A
authors.initials: SA
authors.lastname: Baeten
authors.forename: Rob M P M
authors.initials: RM
authors.lastname: Baltussen
authors.forename: Carin A
authors.initials: CA
authors.lastname: Uyl-de Groot
authors.forename: John
authors.initials: J
authors.lastname: Bridges
authors.forename: Louis W
authors.initials: LW
authors.lastname: Niessen
mesh_terms: D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000601:surgery; D003362:Cost-Benefit Analysis / Q000191:economics; D003661:Decision Support Techniques; D004526:Efficiency; D005260:Female; D006297:Health Services Accessibility / Q000191:economics; D054624:Health Status Disparities; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009367:Neoplasm Staging / Q000191:economics; D009426:Netherlands; D019057:Quality-Adjusted Life Years; D014944:World Health Organization